Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 16;12(11):156.
doi: 10.1038/s41408-022-00743-0.

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Tiziano Barbui  1 , Arianna Ghirardi  2 , Alessandra Carobbio  2 , Arianna Masciulli  2 , Greta Carioli  2 , Alessandro Rambaldi  3   4 , Maria Chiara Finazzi  3   4 , Marta Bellini  3 , Elisa Rumi  5   6 , Daniele Vanni  6 , Oscar Borsani  6 , Francesco Passamonti  7   8 , Barbara Mora  7   8 , Marco Brociner  8 , Paola Guglielmelli  9   10 , Chiara Paoli  9   10 , Alberto Alvarez-Larran  11 , Ana Triguero  11 , Marta Garrote  12 , Helna Pettersson  13 , Björn Andréasson  13 , Giovanni Barosi  14 , Alessandro Maria Vannucchi  9   10
Affiliations

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Tiziano Barbui et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

TB has received personal fees as an advisory board member from AOP Orphan Pharmaceuticals, Italfarmaco, and Novartis, outside the submitted work. AR has received personal fees as an advisory board member from Astellas, Amgen, Celgene BMS, Gilead, Italfarmaco, Novartis, Omeros, Roche, and Sanofi. PG has received speaker honoraria from Novartis and AbbVie and fees from Novartis and AbbVie for participation on advisory boards. AMV has received personal fees for serving on the advisory board and speaker’s fees from AOP Orphan Pharmaceuticals, Incyte, BMS, and Novartis. The remaining authors declare no competing financial interests.

Figures

Fig. 1
Fig. 1. Predictors of post-diagnosis thrombosis estimated by a multivariable Fine and Gray’s competing risk model adjusted for potential confounders (death was considered as a competing event).
sHR Sub-distribution Hazard Ratio, CI Confidence Interval. Hb Hemoglobin (g/dl). JAK2 pos, higher risk: patients with the combination JAK2 V617F mutated and intermediate-2/high IPSS. JAK2 pos, lower risk: patients with the combination JAK2 V617F mutated and low/intermediate -1 IPSS.
Fig. 2
Fig. 2. 10-year Cumulative Incidence Function (CIF) of total thrombosis (death was considered as a competing event).
Cumulative incidence of thrombosis was represented according to IPSS score (panel A), JAK2 mutation (panel B) and their combination (panel C) Lower risk = low and intermediate-1 IPSS categories. Higher risk = Intermediate-2 and high IPSS categories.
See this image and copyright information in PMC

References

    1. Hultcrantz M, Björkholm M, Dickman PW. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population‐based cohort study. Ann Intern Med. 2018;168:317–25. doi: 10.7326/M17-0028. - DOI - PMC - PubMed
    1. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778–82. doi: 10.1182/blood-2009-08-238956. - DOI - PubMed
    1. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95:1788–91. doi: 10.3324/haematol.2010.025064. - DOI - PMC - PubMed
    1. Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017;96:1595–604. doi: 10.1007/s00277-017-3099-2. - DOI - PMC - PubMed
    1. Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pr Thromb Haemost. 2022;6:e12657. - PMC - PubMed

Publication types